109 related articles for article (PubMed ID: 17696959)
1. In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists.
Bocci G; Culler MD; Fioravanti A; Orlandi P; Fasciani A; Colucci R; Taylor JE; Sadat D; Danesi R; Del Tacca M
Eur J Clin Invest; 2007 Sep; 37(9):700-8. PubMed ID: 17696959
[TBL] [Abstract][Full Text] [Related]
2. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD
J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235
[TBL] [Abstract][Full Text] [Related]
3. Effects of chimeric somatostatin-dopamine molecules on human peripheral blood lymphocytes activation.
Casnici C; Lattuada D; Crotta K; Mastrotto C; Franco P; Culler MD; Marelli O
J Neuroimmunol; 2006 Oct; 179(1-2):9-17. PubMed ID: 16904194
[TBL] [Abstract][Full Text] [Related]
4. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis.
Dasgupta P
Pharmacol Ther; 2004 Apr; 102(1):61-85. PubMed ID: 15056499
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic therapy with somatostatin receptor-mediated in situ radiation.
Gulec SA; Gaffga CM; Anthony CT; Su LJ; O'Leary JP; Woltering EA
Am Surg; 2001 Nov; 67(11):1068-71. PubMed ID: 11730223
[TBL] [Abstract][Full Text] [Related]
7. Effects of somatostatin on vascular endothelial growth factor (VEGF) secretion from non-functioning pituitary tumoral cells incubated in vitro.
Ławnicka H; Pisarek H; Kunert-Radek J; Pawlikowski M
Neuro Endocrinol Lett; 2008 Feb; 29(1):113-6. PubMed ID: 18283262
[TBL] [Abstract][Full Text] [Related]
8. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
9. Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.
Zatelli MC; Piccin D; Vignali C; Tagliati F; Ambrosio MR; Bondanelli M; Cimino V; Bianchi A; Schmid HA; Scanarini M; Pontecorvi A; De Marinis L; Maira G; degli Uberti EC
Endocr Relat Cancer; 2007 Mar; 14(1):91-102. PubMed ID: 17395978
[TBL] [Abstract][Full Text] [Related]
10. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1.
Hazarika S; Dokun AO; Li Y; Popel AS; Kontos CD; Annex BH
Circ Res; 2007 Oct; 101(9):948-56. PubMed ID: 17823371
[TBL] [Abstract][Full Text] [Related]
11. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
[TBL] [Abstract][Full Text] [Related]
12. [Somatostatinergic control of Kaposi's sarcoma growth through the inhibition of angiogenesis].
Corsaro A; Thellung S; Villa V; Arena S; Noonan D; Albini A; Schettini G; Florio T
Minerva Endocrinol; 2001 Dec; 26(4):273-6. PubMed ID: 11782715
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor associated with tumor cell proliferation in canine cutaneous squamous cell carcinomas and trichoepitheliomas.
Al-Dissi AN; Haines DM; Singh B; Kidney BA
Vet Pathol; 2007 Nov; 44(6):823-30. PubMed ID: 18039895
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms.
Kodama M; Kitadai Y; Tanaka M; Kuwai T; Tanaka S; Oue N; Yasui W; Chayama K
Clin Cancer Res; 2008 Nov; 14(22):7205-14. PubMed ID: 19010837
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation.
Ferone D; Arvigo M; Semino C; Jaquet P; Saveanu A; Taylor JE; Moreau JP; Culler MD; Albertelli M; Minuto F; Barreca A
Am J Physiol Endocrinol Metab; 2005 Dec; 289(6):E1044-50. PubMed ID: 16046458
[TBL] [Abstract][Full Text] [Related]
16. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
[TBL] [Abstract][Full Text] [Related]
17. Expression of the vascular endothelial growth factor-receptor system in the porcine endometrium throughout the estrous cycle and early pregnancy.
Kaczmarek MM; Waclawik A; Blitek A; Kowalczyk AE; Schams D; Ziecik AJ
Mol Reprod Dev; 2008 Feb; 75(2):362-72. PubMed ID: 17874446
[TBL] [Abstract][Full Text] [Related]
18. Expression of vascular endothelial growth factor-C and its receptor in osteosarcomas.
Park HR; Min K; Kim HS; Jung WW; Park YK
Pathol Res Pract; 2008; 204(8):575-82. PubMed ID: 18440723
[TBL] [Abstract][Full Text] [Related]
19. Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells.
Ludvigsen E; Stridsberg M; Taylor JE; Culler MD; Oberg K; Janson ET
Med Oncol; 2004; 21(3):285-95. PubMed ID: 15456957
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of synthetic somatostatin receptor subtype 4 agonists on acute and chronic airway inflammation and hyperreactivity in the mouse.
Elekes K; Helyes Z; Kereskai L; Sándor K; Pintér E; Pozsgai G; Tékus V; Bánvölgyi A; Németh J; Szuts T; Kéri G; Szolcsányi J
Eur J Pharmacol; 2008 Jan; 578(2-3):313-22. PubMed ID: 17961545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
